Drug Profile
Docosanol
Alternative Names: Abrax; abreva; Herepair; Lidakol; n-DocosanolLatest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator Avanir Pharmaceuticals
- Class Antivirals; Fatty alcohols; Small molecules
- Mechanism of Action Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Herpes simplex virus infections
Most Recent Events
- 06 Jul 2006 Docosanol has been licensed to Healthcare Brands International in Russia, the Ukraine and the EU (excluding Denmark, Finland, Italy, Greece and Sweden)
- 13 Jan 2006 Docosanol has been licensed to Kobayashi Pharmaceutical in Japan
- 12 Oct 2004 Docosanol has been licensed to ACO HUD in Sweden, Norway, Finland and Denmark